Literature DB >> 7699623

Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares.

B A Walz LeBlanc1, D D Gladman, M B Urowitz.   

Abstract

OBJECTIVE: To identify the frequency of serologic activity in the face of clinical quiescence in a large cohort of patients with systemic lupus erythematosus (SLE) followed prospectively in a single center.
METHODS: In a prospective cohort study, patients serologically active but clinically quiescent (SACQ) in 3 consecutive clinic visits were analyzed for the development of a clinical flare over the subsequent year and were evaluated for predictive factors for flare before and during their SACQ period.
RESULTS: Forty-six episodes of SACQ went on to clinical flare within one year while 60 did not. No predictive factors for flare were found either during or before the SACQ period.
CONCLUSIONS: A significant population of patients with SLE are SACQ and must be followed over time and treated only on the basis of clinical criteria.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7699623

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  19 in total

Review 1.  Rheumatology: 2. What laboratory tests are needed?

Authors:  K Shojania
Journal:  CMAJ       Date:  2000-04-18       Impact factor: 8.262

Review 2.  Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future.

Authors:  Chau-Ching Liu; Joseph M Ahearn; Susan Manzi
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

Review 3.  How to monitor SLE in routine clinical practice.

Authors:  M M A Fernando; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

Review 4.  [Early diagnosis in patients with systemic lupus erythematosus (SLE)].

Authors:  M Gaubitz; H Schotte
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

5.  Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.

Authors:  G Zandman-Goddard; M Blank; P Langevitz; L Slutsky; M Pras; Y Levy; O Shovman; T Witte; A Doria; J Rovensky; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

6.  Predictors of kidney disease in a cohort of pediatric patients with lupus.

Authors:  S D Sule; D G Moodalbail; J Burnham; B Fivush; S L Furth
Journal:  Lupus       Date:  2015-02-12       Impact factor: 2.911

7.  Factors associated with remission in patients with systemic lupus erythematosus: new insights into a desirable state.

Authors:  Jorge Romo-Tena; Roberto Reyna-de la Garza; Isaac Bartnicki-Navarrete; Jorge Alcocer-Varela; Diana Gómez-Martin
Journal:  Clin Rheumatol       Date:  2018-07-28       Impact factor: 2.980

Review 8.  Biomarkers for kidney involvement in pediatric lupus.

Authors:  Beatrice Goilav; Chaim Putterman; Tamar B Rubinstein
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

Review 9.  [Modern therapy for systemic lupus erythematosus].

Authors:  R Fischer-Betz; M Schneider
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

10.  Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk.

Authors:  M Bijl; G Horst; H Bootsma; P C Limburg; C G M Kallenberg
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.